Asterion, Inc.

Diurnal Limited

University of Sheffield

Richard Ross

Peter Artymiuk

Jon Sayers

Hiep Huatan

Martin Whitaker

Ian Wilkinson

Norbert Poellinger

Annette Grave

The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.

Parathyroid hormone fusion polypeptide

The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.

Hydrocortisone controlled release formulation

We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists.

Growth hormone fusion proteins with growth hormone receptor agonist activity

The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to pediatric treatment regimens, the treatment of the elderly and non-human animals.

Treatment of adrenal insufficiency

The disclosure relates to pharmaceutical compositions useful in the treatment of adrenal insufficiency in paediatric or elderly subjects.

Composition comprising hydrocortisone

Growth hormone receptor antagonists

We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm.

Lipid composition

We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.

Growth hormone fusion proteins

We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.

Modified growth hormone polypeptides

Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents.

Fusion protein comprising growth hormone and growth hormone receptor

The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Cytokine polypeptides and antibodies containing a signal sequence for the attachment of glycosylphosphatidylinositol

The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of said modified growth hormone binding domains.

Growing community of inventors

Sheffield, United Kingdom

Richard Ross